# Zhen Wang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/zhen-wang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,237 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 69 |
| i10-index | 383 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5100422286 |
| ORCID iD | https://orcid.org/0000-0001-9289-4889 |
| Works | 925 |

## Researcher papers

- [γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer](https://scholariq.org/papers/t17-cells-promote-the-accumulation-and-expansion-of-myeloid-derived-suppressor/)
- [The natural history of untreated severe or critical limb ischemia](https://scholariq.org/papers/the-natural-history-of-untreated-severe-or-critical-limb-ischemia/)
- [Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance](https://scholariq.org/papers/lung-adenocarcinoma-harboring-egfr-t790m-and-in-trans-c797s-responds-to/)
- [A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer](https://scholariq.org/papers/a-comprehensive-review-of-uncommon-egfr-mutations-in-patients-with-non-small/)
- [Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant](https://scholariq.org/papers/ivonescimab-plus-chemotherapy-in-non-small-cell-lung-cancer-with-i-egfr-i/)
- [Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases](https://scholariq.org/papers/prognostic-significance-of-pd-l1-in-patients-with-non-small-cell-lung-cancer-a/)
- [Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial](https://scholariq.org/papers/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Cardiac Fibrosis and Remodeling](https://scholariq.org/topics/cardiac-fibrosis-and-remodeling/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cytokine Signaling Pathways and Interactions](https://scholariq.org/topics/cytokine-signaling-pathways-and-interactions/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.